Sugi Predict
/ Targets
/ PDCD2L
Top predicted compounds (top 20 by supporting neighbours, then confidence)
| Compound | Confidence | Supporting neighbours |
|---|
Clinical trials — most relevant to PDCD2L by text similarity (a relevance ranking, not an exhaustive list)
| Trial | Phase | Status |
|---|
| Effect of Tramadol Versus Morphine on PD1 and PD1-ligand in Patients With Chronic Cancer Pain |
PHASE2/PHASE3 | UNKNOWN |
| PembROlizuMab Immunotherapy Versus Standard Chemotherapy for Advanced prE-treated Malignant Pleural Mesothelioma |
PHASE3 | COMPLETED |
| Tarlatamab and Durvalumab vs. Durvalumab Alone for Limited-Stage-Small Cell Lung Cancer |
PHASE3 | NOT_YET_RECRUITING |
| Pembrolizumab Plus Enfortumab Vedotin in Collecting Duct and Renal Medullary Carcinoma |
PHASE2 | RECRUITING |
| Pembrolizumab (MK-3475) in MM Patients With Residual Disease |
PHASE2 | COMPLETED |
| Investigating Datopotamab Deruxtecan Plus Durvalumab Versus Datopotamab Deruxtecan in Patients With PDL1-negative Metastatic Triple-negative Breast Cancer |
PHASE2 | RECRUITING |
| Pembrolizumab and Induction Chemotherapy in Head and Neck Squamous Cell Carcinoma (PICH Study) |
PHASE1/PHASE2 | WITHDRAWN |
| Pembrolizumab And Tamoxifen Among Women With Advanced Hormone Receptor Positive Breast Cancer And Esr1 Mutation |
PHASE2 | UNKNOWN |
| Anti-PD-1 Monoclonal Antibody in Advanced, Trastuzumab-resistant, HER2-positive Breast Cancer |
PHASE1/PHASE2 | COMPLETED |
| Randomized Phase II, Open-label Efficacy and Safety Study of Second-line Durvalumab Plus Tremelimumab Versus Platinum-based Chemotherapy Alone in Patients With NSCLC and First-line Checkpoint-inhibitor Therapy (Re-Check) |
PHASE2 | WITHDRAWN |
| Small Cell Lung Carcinoma Trial With Nivolumab and IpiliMUmab in LImited Disease |
PHASE2 | COMPLETED |
| Study on the Safety and Tolerability of PD-1 Knockout Tumor-infiltrating T Cells (TILs) in the Treatment of Advanced Colorectal Cancer |
PHASE1 | RECRUITING |
| A First-in-human Study to Learn How Safe the Study Drug BAY2965501 is, Find the Best Dose (Single Drug & Combination), How it Affects the Body, What Maximum Amount Can be Given, How it Moves Into, Through and Out of the Body, How it Acts on Different Tumors in Participants With Advanced Solid Tumors |
PHASE1 | ACTIVE_NOT_RECRUITING |
| Phase 1 Study of HLX10, a Monoclonal Antibody Targeting Programmed Death-1 (PD-1) in Patients With Advanced Solid Tumors |
PHASE1 | UNKNOWN |
| Safety and Pharmacology of SNX-5422 Plus Carboplatin and Paclitaxel in Subjects With Solid Tumors |
PHASE1 | COMPLETED |
| Modulatory Effect of Prodigiosin or Pioglitazone on TIME and the Crosstalk to Immune-Checkpoint Protein(s) |
nan | NOT_YET_RECRUITING |
| Effect of Severe Trauma on PD1 and Its Legend (PD1/L1) on T Lymphocytes and Correlation With Mortality |
nan | UNKNOWN |
| Effect of Anesthesia on Expression of Programmed Death-1 and Programmed Death-1 Ligand in Breast Cancer |
nan | UNKNOWN |
| Role of Programmed Death Ligand 1 in Colorectal Cancer |
nan | NOT_YET_RECRUITING |
| Correlation Between Specific Gene Mutationand Local Immune Microenvironment and Immunotherapy Efficacy in NSCLC |
nan | UNKNOWN |
| Co-stimulatory Markers and Vitamin D Status in Anti-PD1 Treated Melanoma Patients |
nan | COMPLETED |
| Immunohistochemical Assessment of Programmed Death ligand1 and LC3B in GBM |
nan | UNKNOWN |
| Assessing the Polygenic Burden of Rare Disruptive Mutations in Parkinson's Disease |
nan | UNKNOWN |
| Multicenter Study of Immunoadsorption in Dilated Cardiomyopathy |
nan | COMPLETED |
| Patient-Derived Organoids to Functionally Characterize Chemotherapy Resistance in Breast Cancer |
nan | NOT_YET_RECRUITING |
| Genetic Characterization of Parkinson's Disease |
nan | COMPLETED |
| Diagnostic Tools for Parkinson's Disease |
nan | COMPLETED |
| Establishment of Human Cellular Disease Models for Wilson Disease |
nan | COMPLETED |
| Immune Checkpoint Inhibitors Nephrotoxicity |
nan | RECRUITING |
| Pembrolizumab (MK-3475) in Patients With Recurrent Malignant Glioma With a Hypermutator Phenotype |
nan | ACTIVE_NOT_RECRUITING |
Related proteins — ESM-2 sequence neighbours (a PDCD2L binder may also engage these)